esmo 2014 advanced programme · management of breast cancer in elderly patients etienne brain,...

esmocongress.org

Organiser

ADVANCED PROGRAMME

ESMO 2014

IMPORTANT DEADLINES07 May 2014 Abstract submission and travel grant applications

18 June 2014 Early registration

23 July 2014 Group registration, participant names to be given

20 August 2014 Late-breaking abstract submission

20 August 2014 Late registration

26-30 SEPTEMBER 2014Madrid, Spain

9Session timings may be subject to change within the same day

SCIENTIFIC COMMITTEECharles Swanton, London, UK, Chair

Jiri Bartek, Copenhagen, DenmarkRené Bernards, Amsterdam, NetherlandsRebecca Burrell, London, UKCarlos Caldas, Cambridge, UKRobert Gatenby, Tampa, FL, USRamaswamy Govindan, St. Louis, MO, US

Jos Jonkers, Amsterdam, NetherlandsTak Mak, Toronto, ON, CanadaCarlo Maley, San Franscisco, CA, USASheila Singh, Hamilton, ON, CanadaYosef Yarden, Rehovot, Israel

BASIC SCIENCE AND TRANSLATIONAL RESEARCH

Saturday, 27 September 201410:30/11:30

PATIENT CASESCancer evolution: What can we learn from N=1 molecular studies?Co-Chairs: Michael Taylor, Toronto, ON, Canada and Tariq Enver, London, UKEvolution of acute lymphoblastic leukemia (ALL) in identical twinsTariq Enver, London, UKClonal evolution of childhood cancers Michael Taylor, Toronto, ON, CanadaDiscussion

Sunday, 28 September 201409:15/ 10:45

JOINT SYMPOSIUM: ESMO - JSMO How to implicate genome sequencing data in oncology Co-Chairs: Jean-Yves Douillard, St. Herblain, France and Atsushi Ohtsu, Kashiwa, JapanIntroductionJean-Yves Douillard, St. Herblain, FrancePotentially druggable gene alterations in gastrointestinal cancerTatsuhiro Shibata, Tokyo, JapanA new molecular taxonomy for colorectal cancer – What are the therapeutic implications?To be announcedNew insight of sequencing data in lung cancerKazuto Nishio, Osaka, JapanOvercoming implementation challenges of personalised cancer therapy in patients with breast cancerFabrice André, Villejuif, FranceConclusionsAtsushi Ohtsu, Kashiwa, Japan

13:00/13:45

KEYNOTE LECTURE Reclassifying cancer through genomicsChair: Jos Jonkers, Amsterdam, NetherlandsSpeaker: Michael Stratton, London, UK

Monday, 29 September 2014 11:00/12:30

SPECIAL SYMPOSIUM Genomic instability from bench to bedsideChair: Sheila Singh, Hamilton, ON, CanadaCo-Chair: Charles Swanton, London, UKIntroduction Charles Swanton, London, UKThe emerging role of HELQ in homologous recombination repair in ovarian cancerRebecca Burrell, London, UKReplication stress and DNA damage response in solid tumoursJiri Bartek, Copenhagen, DenmarkThe interface between cancer numerical and structural chromosomal instability: Mechanisms accelerating cancer diversityRené Medema, Amsterdam, NetherlandsTargeting cancer aneuploidy: Light at the end of the tunnel?Tak Mak, Toronto, ON, CanadaConclusions and clinical perspectivesSheila Singh, Hamilton, ON, Canada

10 Session timings may be subject to change within the same day

BREAST CANCER

Saturday, 27 September 2014 09:00/10:30

EDUCATIONAL SESSIONUpdate in the management of metastatic breast cancers Chair: Angelo Di Leo, Prato, ItalyCo-Chair: Hernan Cortes-Funes, Madrid, SpainIntegration of molecular analyses in the management of metastatic breast cancerNicholas Turner, London UKHormonal therapyIan Smith, London, UKOptimal therapy for R2 positiveAngelo Di Leo, Prato, Italy

11:00/12:30

EDUCATIONAL SESSIONManagement of breast cancer in specific populationsChair: Fatima Cardoso, Lisbon, Portugal Co-Chair: to be announcedManagement of breast cancer in elderly patientsEtienne Brain, Saint Cloud, FranceManagement of breast cancer in very young and pregnant womenSybille Loibl, Neu-Isenburg, Germany Management of breast cancer in malesFatima Cardoso, Lisbon, Portugal

16:00/17:30

EDUCATIONAL SESSION (REPETITION)Management of breast cancer in specific populationsChair: Fatima Cardoso, Lisbon, Portugal Co-Chair: to be announcedManagement of breast cancer in elderly patientsEtienne Brain, Saint Cloud, FranceManagement of breast cancer in very young and pregnant womenSybille Loibl, Neu-Isenburg, Germany Management of breast cancer in malesFatima Cardoso, Lisbon, Portugal

Sunday, 28 September 201408:00/09:00

PATIENT CASESTargeting intrinsic subtypes of metastatic breast cancer: The spectrum of sensitivity to endocrine therapyCo-Chairs: Philippe Bedard, Toronto, ON, Canada and Javier Cortes, Barcelona, Spain Overcoming resistance in ER positive diseasePhilippe Bedard, Toronto, ON, CanadaDealing with heterogeneity of triple negative breast cancer: From luminal androgen receptor to mesenchimal stem like subtypeJavier Cortes, Barcelona, SpainDiscussion

09:15/10:45

SPECIAL SYMPOSIUM Residual disease after neoadjuvant therapiesChair: Evandro de Azambuja, Brussels, BelgiumCo-Chair: Suzette Delaloge, Villejuif, FranceIntroduction Suzette Delaloge, Villejuif, FranceQuantifying post-neo adjuvant therapy residual disease and its impact on relapse riskFraser Symmans, Houston, TX, USBiological profiling of residual diseaseFrederique Penault-Llorca, Clermont-Ferrand, FranceMolecular imaging: Are we able to predict for residual disease?Andreas Makris, Northwood, UKHow to design clinical trials in a post neo-adjuvant setting?Andrew Tutt, London, UKConclusions and clinical perspectivesEvandro de Azambuja, Brussels, Belgium

14:15/15:45

EDUCATIONAL SESSION (REPETITION)Update in the management of metastatic breast cancersChair: Angelo Di Leo, Prato, ItalyCo-Chair: Hernan Cortes-Funes, Madrid, SpainIntegration of molecular analyses in the management of metastatic breast cancerNicholas Turner, London UKHormonal therapyIan Smith, London, UKOptimal therapy for R2 positiveAngelo Di Leo, Prato, Italy

SCIENTIFIC COMMITTEE (EARLY STAGE)Evandro De Azambuja, Brussels, Belgium, Chair

Hatem Azim, Brussels, BelgiumAgusti Barnadas, Barcelona, SpainFatima Cardoso, Lisbon, PortugalBoon Chua, Melbourne, AustraliaAngelo Di Leo, Prato, ItalyPeter Dubsky, Vienna, Austria

Sabine C. Linn, Amsterdam, NetherlandsCarlo Palmieri, Liverpool, UKAlastair Thompson, Dundee, UKAndrew Tutt, London, UKGiuseppe Viale, Milan, Italy


SCIENTIFC COMMMITEE (METASTATIC)Giuseppe Curigliano, Milan, Italy, Chair

Philippe Bedard, Toronto, ON, CanadaJavier Cortes, Barcelona, SpainCarmen Criscitiello, Milan, ItalyCarsten Denkert, Berlin, GermanyLuca Gianni, Milan, ItalyRoger Gomis, Barcelona, Spain

Per Karlsson, Gothenburg, SwedenAntonio Llombart, Valencia, SpainSherene Loi, Melbourne, AustraliaSibylle Loibl, Neu-Isenburg, GermanyNicholas Turner, London, UK

Monday, 29 September 201408:00/09:00

CHALLENGE YOUR EXPERT (CYE)Adjuvant treatment of breast cancerSpeaker: Martine Piccart, Brussels, Belgium

09:15/10:45

SPECIAL SYMPOSIUMCancer immunotherapy in breast cancer: Dream or reality?Chair: Giuseppe Curigliano Milan, ItalyCo-Chair: Sherene Loi, Melbourne, AustraliaIntroduction Giuseppe Curigliano Milan, ItalyModulation of immune response in breast cancer and clinical implications of tumour dormancySherene Loi, Melbourne, AustraliaDiagnostic and therapeutic implications of tumour-infiltrating lymphocytes in breast cancerCarsten Denkert, Berlin, Germany

Contribution of immune response to anti-tumour effect of chemotherapy Carmen Criscitiello, Naples, ItalyDesign of the ideal trial with immunotherapeuticsGiuseppe Curigliano Milan, ItalyConclusions and clinical perspectivesSherene Loi, Melbourne, Australia

14:15/15:45

JOINT SYMPOSIUM: ESMO - ESTRO - ESSOIntegration of local therapy with systemic treatment in oligometastatic breast cancerCo-Chairs: Christoph Zielinski, Vienna, Austria; Philip Poortmans, Tilburg, Netherlands and Riccardo A. Audisio, St. Helens, UK IntroductionChristoph Zielinski, Vienna, AustriaCombining systemic treatment with radiation therapy: Quantifying the therapeutic gainPer Karlsson, Gothenburg, SwedenDesign of clinical trials integrating local treatments with systemic therapy for M1 diseaseTo be announcedThe role of surgery for M1 breast cancerMarjut Leidenius, Helsinki, FinlandThe role of radiation therapy for M1 breast cancerPhilip Poortmans, Tilburg, NetherlandsConclusionsRiccardo A. Audisio, St. Helens, UK

16:00/17:00

PATIENT CASESChallenges in managing breast cancer in young patientsCo-Chairs: Hatem A. Azim, Brussels, Belgium; Marco Colleoni, Milan, Italy and Sabine Linn, Amsterdam, Netherlands Genetic testing: When and for whom?Sabine Linn, Amsterdam, NetherlandsFertility counselling: What are the options?Hatem A. Azim, Brussels, Belgium, Optimal adjuvant hormonal therapy in premenopausal womenMarco Colleoni, Milan, ItalyDiscussion

Tuesday, 30 September 201408:00/09:00

CYE (REPETITION)Adjuvant treatment of breast cancerSpeaker: Martine Piccart, Brussels, Belgium


CNS TUMOURS

Sunday, 28 September 2014 09:15/10:45

EDUCATIONAL SESSIONActual issues in neurooncologyChair: Roger Stupp, Zurich, SwitzerlandCo-Chair: Mario Campone, St. Herblain, FranceBrain metastases: To treat or not to treat?Roger Stupp, Zurich, Switzerland Molecular marker-based clinical decision-making todayMichael Weller, Zurich, SwitzerlandApproaches to recurrent glioblastomaAlba Brandes, Bologna, Italy

11:45/12:45

PATIENT CASES Response, neurological function and other objectives in the management of patients with brain metastasesCo-Chairs: Martin Bendszus, Heidelberg, Germany; Anthony Chalmers, Glasgow, UK, and Enrico Franceschi, Bologna, ItalyWhat type of radiotherapy is indicated in brain metastases?Anthony Chalmers, Glasgow, UKSystemic therapy instead or in addition to irradiation?Enrico Franceschi, Bologna, ItalyChallenges and pitfalls in radiological response assessment of brain metastasesMartin Bendszus, Heidelberg, GermanyDiscussion

14:15/15:45

SPECIAL SYMPOSIUMCurrent concepts and future avenues in meningiomaChair: Jörg-Christian Tonn, Munich, GermanyCo-Chair: Matthias Preusser, Vienna, AustriaIntroduction Jörg-Christian Tonn, Munich, GermanyMeningioma: What can we learn from the biology for precision medicine?Michel Kalamarides, Paris, FranceClassification and molecular pathology of meningiomasChristian Mawrin, Magdeburg, GermanyRadiotherapy of meningiomasDamien Weber, Geneva, SwitzerlandMolecular targeted, systemic therapies for meningiomasMatthias Preusser, Vienna, AustriaConclusions and clinical perspectivesMatthias Preusser, Vienna, Austria

SCIENTIFIC COMMITTEERoger Stupp, Zurich, Switzerland, Chair

Carmen Balaña, Barcelona, SpainElizabeth Cohen-Jonathan-Moyal, Toulouse, FranceEnrico Franceschi, Bologna, ItalyEvanthia Galanis, Rochester, MN, USAKhé Hoang-Xuan, Paris, FranceStefan Pfister, Heidelberg, Germany

Matthias Preusser, Vienna, AustriaGuido Reifenberger, Düsseldorf, GermanyJoan Seoane, Barcelona, SpainMartin van den Bent, Rotterdam, NetherlandsColin Watts, Cambridge, UK


DEVELOPMENTAL THERAPEUTICS


JOINT SYMPOSIUM: ESMO - CSCO Global collaboration in phase I cancer drug developmentCo-Chairs: Yi-Long Wu, Guangzhou, China andto be announced Introduction Yi Long Wu, Guangzhou, ChinaPhase I cancer drug development in ChinaJin Li, Shanghai, ChinaPhase I cancer drug development in EuropeTo be announcedHow can pharmaceutical companies facilitate this global effort?To be announcedLung Cancer Asia Study Group: EastYi-Long Wu, Guangzhou, ChinaConclusions To be announced


SPECIAL SYMPOSIUMMolecular profiling: Challenges and perspectivesChair: Christian Dittrich, Vienna, AustriaCo-Chair: Jean-Charles Soria, Villejuif, FranceIntroductionJean-Charles Soria, Villejuif, FranceHow to design the trials to meet the perspectives of personalised cancer medicineSumithra Mandrekar, Rochester, NY, US Platforms for tumour sequencing: Pertinence and practicabilityMartijn Lolkema, Utrecht, NetherlandsOverview of trials testing tumour molecular profiling Jean-Charles Soria, Villejuif, FranceTargets, targets everywhere but not a drug to giveUdai Banerji, London, UK Conclusions and clinical perspectivesChristian Dittrich, Vienna, Austria


PATIENT CASES Demonstrating the emergence of resistanceCo-Chairs: Elisabeth de Vries, Groningen, Netherlands, and Ruth Plummer, Newcastle upon Tyne, UKHow to overcome drug resistance Ruth Plummer, Newcastle upon Tyne, UKMolecular imaging to demonstrate changes in tumour characteristics over the time Elisabeth de Vries, Groningen, NetherlandsDiscussion

13:00/13:50

KEYNOTE LECTURERational drug combinationsChair: Timothy Yap, Sutton, UKConcepts and pre-clinical proof of principleRené Bernards, Amsterdam, NetherlandsClinical results and future perspectivesJan Schellens, Amsterdam, Netherlands

SCIENTIFIC COMMITTEEChristian Dittrich, Vienna, Austria, Chair

Ahmad Awada, Brussels, BelgiumUdai Banerji, Sutton, UKElisabeth de Vries, Groningen, NetherlandsElizabeth A. Eisenhauer, Kingston, ON, CanadaManuel Hidalgo, Madrid, SpainAnnette K. Larsen, Paris, France

Ruth Plummer, Newcastle upon Tyne, UKRoberto Salgado, Brussels, BelgiumPatrick Schöffski, Leuven, BelgiumGiampaolo Tortora, Verona, ItalyChristopher Twelves, Leeds, UK


www.staralliance.com

Information correct as of 06/2013

BOOKING YOUR OWN CONFERENCE TRAVEL IS EASY AS ABCWITH THE GLOBAL ONLINE BOOKING TOOL FROM STAR ALLIANCE CONVENTIONS PLUSNo matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to ESMO 2014 in Madrid.

And with over 21,900 flights a day to 1,329 destinations across 195 countries, our 28 member airlines extend the same choice to any future conferences you are planning to attend.

You can also save money when you book your flights. Simply quote the Convention Code SK07A03 and you plus one travelling companion will receive a special discount. Better still, no matter which Star Alliance member airline’s frequent flyer programme you belong to, you can earn and redeem miles across all 28 airlines.

For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to www.staralliance.com/conventionsplus

SA_ConventionsPlus_AD_A4_2013-06_generic.indd 1 26.02.14 09:53

FAMILIAL CANCERS AND GENETIC SYNDROMES


SPECIAL SYMPOSIUMGermline genetics: Important issues for oncologistsChair: Dominique Stoppa-Lyonnet, Paris, FranceCo-Chair: Rosalind Eeles, Sutton, UKIntroduction Dominique Stoppa-Lyonnet, Paris, France Current application of genetic variants to clinical managementGareth Evans, Sutton, UKConsiderations for the oncologist when referring for testing: Which tests are available and why?Thierry Frebourg, Rouen, France Genetic risk and its implications for cancer surveillanceRosalind Eeles, Sutton, UK Considerations for the oncologist when treating cancer patients with germline mutationsGillian Mitchell, Melbourne, AustraliaConclusions and clinical perspectivesRosalind Eeles, Sutton, UK


PATIENT CASES Clinical and ethical issues in cancer geneticsCo-Chairs: Anneke Lucassen, Southampton, UK and Fred Menko, Amsterdam, NetherlandsEarly onset renal cancerFred Menko, Amsterdam, NetherlandsEthical issues surrounding genetic resultsAnneke Lucassen, Southampton, UK Discussion

SCIENTIFIC COMMITTEERosalind Eeles, Sutton, UK, Chair

Judith Balmaña, Barcelona, SpainElena Castro, Sutton, UKGareth Evans, Manchester, UKKari Hemminki, Heidelberg, GermanyShirley Hodgson, London, UK

Fred Menko, Amsterdam, NetherlandsGillian Mitchell, Melbourne, AustraliaKenneth Muir, Coventry, UKDominique Stoppa-Lyonnet, Paris, FranceHans Vasen, Leiden, Netherlands

www.staralliance.com

Information correct as of 06/2013

BOOKING YOUR OWN CONFERENCE TRAVEL IS EASY AS ABCWITH THE GLOBAL ONLINE BOOKING TOOL FROM STAR ALLIANCE CONVENTIONS PLUSNo matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to ESMO 2014 in Madrid.

And with over 21,900 flights a day to 1,329 destinations across 195 countries, our 28 member airlines extend the same choice to any future conferences you are planning to attend.

You can also save money when you book your flights. Simply quote the Convention Code SK07A03 and you plus one travelling companion will receive a special discount. Better still, no matter which Star Alliance member airline’s frequent flyer programme you belong to, you can earn and redeem miles across all 28 airlines.

For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to www.staralliance.com/conventionsplus

SA_ConventionsPlus_AD_A4_2013-06_generic.indd 1 26.02.14 09:53

16

GASTROINTESTINAL TUMOURS


EDUCATIONAL SESSIONClinical impact of tumour biology in the management of oesophago-gastric cancerChair: Florian Lordick, Leipzig, GermanyCo-Chair: Fernando Rivera Herrero, Madrid, SpainShould locally advanced adenocarcinoma of the oesophagus and of the gastroesophageal junction (GEJ) be managed in the same way?Michael Stahl, Essen, GermanySurgery: Does response to preoperative therapy modify the extension of surgical resection? When is salvage surgery indicated?Arnulf Hölscher, Cologne, GermanyNovel targets in the treatment of advanced gastric cancer: What exists already and what comes next?Florian Lordick, Leipzig, Germany

14:15/15:45

EDUCATIONAL SESSIONOptimising the treatment of colorectal cancerChair: Richard Adams, Cardiff, UKCo-Chair: to be announcedAre there any useful tools when deciding about adjuvant chemotherapy?Richard Adams, Cardiff, UKHow to select first line chemotherapy in metastatic colorectal cancerClaus-Henning Koehne, Oldenburg, GermanyOptimising biomarkers based management beyond KRASSabine Tejpar, Leuven, Belgium

16:00/17:30

EDUCATIONAL SESSIONA multidisciplinary approach to locoregionally advanced rectal cancerChair: Robert Glynne-Jones, Northwood, UKCo-Chair: Eduardo Diaz Rubio, Madrid, SpainRadiotherapy: Which type and for whom?Robert Glynne-Jones, Northwood, UKNeoadjuvant and adjuvant chemotherapy: Is there a standard of care or not yet?Andrés Cervantes, Valencia, SpainIs there still room for improvement in surgery for locoregionally advanced rectal cancer?Cornelis van de Velde, Leiden, Netherlands


PATIENT CASES Challenges in oligometastatic disease: Ways towards long-term survival of metastatic colorectal cancerCo-Chairs: Theo Ruers, Amsterdam, Netherlands and Alberto Sobrero, Genoa, ItalyIrresectable liver metastases: What do local ablative treatments contribute?Theo Ruers, Amsterdam, NetherlandsWhat drives long-term survival with systemic treatment? Alberto Sobrero, Genoa, ItalyDiscussion

11:00/12:30

EDUCATIONAL SESSION (REPETITION)A multidisciplinary approach to locoregionally advanced rectal cancerChair: Robert Glynne-Jones, Northwood, UKCo-Chair: Eduardo Eduardo Diaz Rubio, Madrid, SpainRadiotherapy: Which type and for whom?Robert Glynne-Jones, Northwood, UKNeoadjuvant and adjuvant chemotherapy: Is there a standard of care or not yet?Andrés Cervantes, Valencia, SpainIs there still room for improvement in surgery for locoregionally advanced rectal cancer?Cornelis van de Velde, Leiden, Netherlands

14:15/15:45

SPECIAL SYMPOSIUM Advances in precision medicine of metastatic colorectal cancerChair: Will Steward, Leicester, UKCo-Chair: Thomas Seufferlein, Ulm, GermanyIntroduction Thomas Seufferlein, Ulm, GermanyNew molecular classification of colorectal cancerKrisztian Homicsko, Lausanne, SwitzerlandEmerging druggable targets in colorectal cancerFederica Di Nicolantonio, Candiolo, ItalySignal transduction inhibitors and pipeline drugsJosep Tabernero, Barcelona, SpainImmunotherapy and vaccinesPierpaolo Correale, Siena, ItalyLiquid biopsies and “on treatment” markersGerald Prager, Vienna, AustriaConclusions and clinical perspectivesWill Steward, Leicester, UK

SCIENTIFIC COMMITTEE (COLORECTAL)Dirk Arnold, Freiburg, Germany, Chair

Eduardo Díaz-Rubio, Madrid, Spain Federica Di Nicolantonio, Candiolo, ItalyAxel Grothey, Rochester, MN, USAThomas Grünberger, Vienna, AustriaCorrie Marijnen, Leiden, NetherlandsPer Pfeiffer, Odense, Denmark

Gerald Prager, Vienna, AustriaThomas Seufferlein, Ulm, GermanyMattew Seymour, Leeds, UKAlberto Sobrero, Genoa, ItalySabine Tejpar, Leuven, BelgiumChristophe Tournigand, Créteil, France



MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)Locally advanced pancreatic cancerChair: Eric Van Cutsem, Leuven, BelgiumCo-Chair: Bengt Glimelius, Uppsala, SwedenRadiation oncologyBengt Glimelius, Uppsala, Sweden Medical oncologyEric Van Cutsem, Leuven, Belgium Discussion

11:45/12:45

MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)Sequence of treatment in colorectal cancer with synchronous metastasesChair: Bernard Nordlinger, Boulogne, FranceCo-Chair: Gunnar Folprecht, Dresden, GermanySurgeryBernard Nordlinger, Boulogne, FranceMedical oncologyGunnar Folprecht, Dresden, GermanyDiscussion

11:45/12:45

PATIENT CASESIntegrating systemic and locoregional therapies in a patient with advanced hepatocellular carcinoma (HCC)Co-Chairs: Riccardo Lencioni, Pisa, Italy and Chris Verslype, Leuven, BelgiumSystemic therapyChris Verslype, Leuven, BelgiumLocoregional therapyRiccardo Lencioni, Pisa, ItalyDiscussion

14:1515:15

MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)Multidisciplinary management of peritoneal carcinomatosisChair: Dominique Elias, Villejuif, FranceCo-Chair: Cornelis Punt, Amsterdam, NetherlandsSurgeryDominique Elias, Villejuif, FranceMedical oncologyCornelis Punt, Amsterdam, NetherlandsDiscussion

14:15/15:45

EDUCATIONAL SESSION (REPETITION)Optimising the treatment of colorectal cancerChair: Richard Adams, Cardiff, UKCo-Chair: to be announcedAre there any useful tools when deciding about adjuvant chemotherapy?Richard Adams, Cardiff, UKHow to select first line chemotherapy in metastatic colorectal cancerClaus-Henning Koehne, Oldenburg, GermanyOptimising biomarkers based management beyond KRASSabine Tejpar, Leuven, Belgium

16:00/17:30

SPECIAL SYMPOSIUMTowards personalised medicine in gastric, pancreatic and liver cancer: From “omics” research to treatmentChair: Erika Martinelli, Naples, ItalyCo-Chair: Michel Ducreux, Villejuif, FranceIntroduction Michel Ducreux, Villejuif, FranceWhat are the new tools available?Peter Schirrmacher, Heidelberg, GermanyHepatocellular carcinoma (HCC)Augusto Villanueva, London, UKPancreatic cancerManuel Hidalgo, Madrid, SpainGastric cancerPatrick Tan, SingaporeConclusions and clinical perspectivesErika Martinelli, Naples, Italy

SCIENTIFIC COMMITTEE (NON-COLORECTAL)Andrés Cervantes, Valencia, Spain, Chair

Regina Beets-Tan, Maastricht, NetherlandsFátima Carneiro, Porto, PortugalThierry Conroy, Vandoeuvre-les-Nancy, FranceMichel Ducreux, Villejuif, FranceKarin Haustermans, Leuven, BelgiumFlorian Lordick, Leipzig, Germany

Teresa Macarulla, Barcelona, SpainErika Martinelli, Naples, ItalyFernando Rivera, Santander, SpainJuan Valle, Manchester, UKChris Verslype, Leuven, Belgium


GENITOURINARY TUMOURS


CHALLENGE YOUR EXPERT (CYE)Management of relapsed germ cell tumoursSpeaker: Joerg Beyer, Zurich, Switzerland

08:00/09:00

PATIENT CASESMultimodal treatment approaches in bladder cancerCo-Chairs: Thierry Lebret, Suresnes, France; Nicholas James, Birmingham, UK and David Solit, New York, NY USThe role of surgery in advanced bladder cancerThierry Lebret, Suresnes, FrancePrecision drug treatment for bladder cancerDavid Solit, New, York, NY, USIs surgery always necessary?Nicholas James, Birmingham, UKDiscussion

14:00/15:45

SPECIAL SYMPOSIUMPrecision medicine in prostate cancerChair: Mark Rubin, New York, NY, USCo-Chair: Eleni Efstathiou, Athens, GreeceIntroduction Eleni Efstathiou, Athens, GreeceProstate carcinogenesis: What have we learnt from next generation sequencing?Levi A. Garraway, Boston, MA, USDo we need a new taxonomy for prostate cancer?Mark Rubin, New York, NY, USWill circulating biomarkers help to deliver precision medicine?David Olmos, Madrid, SpainImmunotherapy for prostate cancer?Charles Drake, Baltimore, MD, USWhere next for precision medicine for prostate cancer?Eleni Efstathiou, Athens, GreeceConclusions and clinical perspectivesMark Rubin, New York, NY, US

16:00/17:30

EDUCATIONAL SESSIONUpdate in genitourinary oncologyChair: Bernard Escudier, Villejuif, France Co-Chair: Ian Tannock, Toronto, ON, CanadaOptimal sequence of treatment for metastatic prostate cancerCora Sternberg, Rome, ItalyHow to deal with unresectable and inoperable bladder cancerMaria de Santis, Vienna, AutriaTreatment of metastatic renal cell carcinoma (RCC): Present and futureBernard Escudier, Villejuif, France


CYE (REPETITION)Management of relapsed germ cell tumoursSpeaker: Joerg Beyer, Zurich, Switzerland

11:00/12:30

EDUCATIONAL SESSION (REPETITION)Update in genitourinary oncologyChair: Bernard Escudier, Villejuif, France Co-Chair: Ian Tannock, Toronto, ON, Canada Optimal sequence of treatment for metastatic prostate cancerCora Sternberg, Rome, ItalyHow to deal with unresectable and inoperable bladder cancerMaria de Santis, Vienna, AusriaTreatment of metastatic renal cell carcinoma (RCC): Present and futureBernard Escudier, Villejuif, France


PATIENT CASESTreatment of castration-resistant prostate cancer (CRPC) in special situationsCo-Chairs: Gerhardt Attard, Surrey, UK, Anna Falanga, Bergamo, Italy and Stephane Oudard, Paris, FranceTreating elderly patientsStephane Oudard, Paris, FranceWhen is prostate cancer truly androgen independent?Gerhardt Attard, Surrey, UKBone marrow carcinosis and disseminated intravascular coagulation (DIC)Anna Falanga, Bergamo, ItalyDiscussion

09:15/10:45

SPECIAL SYMPOSIUMBeyond tumour heterogeneity: New pathways in kidney cancerChair: Viktor Grünwald, Hannover, GermanyCo-Chair: Cora Sternberg, Rome, ItalyIntroduction Cora Sternberg, Rome, ItalyMolecular classification of kidney cancer Andrew Futreal, Houston, TX, USPrecision medicine in kidney cancer and clinical trial designsJames Larkin, London, UKImmunotherapy: Myth or reality?David McDermott, Boston, MA, USNew drugs and new targets (phase I)Emiliano Calvo, Madrid, SpainConclusions and clinical perspectivesViktor Grünwald, Hannover, Germany

19

SCIENTIFIC COMMITTEE (PROSTATE)Eleni Efstathiou, Athens, Greece, Chair

Gerhardt Attard, Sutton, UKKarim Fizazi, Villejuif, FranceSilke Gillessen, St. Gallen, SwitzerlandAxel Heidenreich, Aachen, GermanyDavid Olmos, Madrid, SpainStephane Oudard, Paris, France

Chris Parker, Sutton, UKMark Rubin, New York, NY, USJack Schalken, Nijmegen, NetherlandsAvishay Sella, Zerifin, IsraelAnders Widmark, Umeå, Sweden

SCIENTIFIC COMMITTEE (NON-PROSTATE)James Larkin, London, UK, Chair

Michael Aitchison, Glasgow, UKAxel Bex, Amsterdam, NetherlandsEmiliano Calvo, Madrid, SpainMaria De Santis, Vienna, AustriaBernard Escudier, Villejuif, FranceViktor Grünwald, Hannover, Germany

Nicholas James, Birmingham, UKArnaud Mejean, Paris, FranceGerald Mickisch, Bremen, GermanyManuela Schmidinger, Vienna, AustriaCora Sternberg, Rome, Italy


GYNAECOLOGICAL CANCERS


CHALLENGE YOUR EXPERT (CYE)Medical treatment for advanced endometrial cancerSpeaker: Cristiana Sessa, Bellinzona, Switzerland

14:15/15:45

EDUCATIONAL SESSIONOvarian cancerChair: Antonio Gonzalez Martin, Madrid, SpainCo-Chair: Nicoletta Colombo, Milan, ItalyAntiangiogenic therapy: Where in the disease pathway and which patients?Antonio Gonzalez Martin, Madrid, SpainHow to recognise and treat low grade tumoursJonathan Ledermann, London, UKTreatment for relapsing patientsSandro Pignata, Naples, Italy


CYE (REPETITION)Medical treatment for advanced endometrial cancer

Speaker: Cristiana Sessa, Bellinzona, Switzerland

09:30/10:30

MULTIDISCIPLINARY INTERACTIVE SESSION (MIS) Management of localised endometrial cancerChair: Carien L. Creutzberg, Leiden, NetherlandsCo-Chair: Mansoor Mirza, Copenhagen, DenmarkRadiotherapyCarien L. Creutzberg, Leiden, NetherlandsClinical oncologyMansoor Mirza, Copenhagen, DenmarkDiscussion

11:00/12:30

SPECIAL SYMPOSIUMTargeted therapy in gynaecological cancerChair: Andres Poveda, Valencia, SpainCo-Chair: Eric Pujade-Lauraine, Paris, FranceIntroduction Eric Pujade-Lauraine, Paris, FranceEmerging molecular targets in gynaecological cancerDavid Huntsman, Vancouver, BC, CanadaThe impact of targeted therapy in cervical and endometrial cancerAna Oaknin, Barcelona, SpainTargeted therapy of ovarian cancer: Beyond angiogenesis Nicoletta Colombo, Milan, ItalyThe coming decadeMichael Bookman, Tucson, AZ, USConclusions and clinical perspectivesAndres Poveda, Valencia, Spain

14:15/15:45

EDUCATIONAL SESSION (REPETITION) Ovarian cancerChair: Antonio Gonzalez Martin, Madrid, SpainCo-Chair: Nicoletta Colombo, Milan, ItalyAntiangiogenic therapy: Where in the disease pathway and which patients?Antonio Gonzalez Martin, Madrid, SpainHow to recognise and treat low grade tumoursJonathan Ledermann, London, UKTreatment for relapsing patientsSandro Pignata, Naples, Italy

Monday, 29 September 2014 08:00/09:00

PATIENT CASESPrimary surgery or neoadjuvant chemotherapy for ovarian cancer: How should we select the patients?Co-Chairs: Charles Gourley, Edinburgh, UK; Christian Marth, Innsbruck, Austria and Isabelle Ray-Coquard, Lyon, FranceThe role of upfront surgeryChristian Marth, Innsbruck, AustriaBest neo-adjuvant therapy: Options for selected patients Isabelle Ray-Coquard, Lyon, FranceIs there a molecular analysis that can help us define a subgroup of patients?Charles Gourley, Edinburgh, UKDiscussion

SCIENTIFIC COMMITTEEAndres Poveda, Valencia, Spain, Chair

Michael Bookman, Tucson, AZ, USAntonio González Martin, Madrid, SpainPhilipp Harter, Essen, GermanyJonathan Ledermann, London, UKChristian Marth, Innsbruck, AustriaMansoor Mirza, Copenhagen, Denmark

José Palacios Calvo, Madrid, SpainTimothy Perren, Leeds, UKSandro Pignata, Naples, ItalyEric Pujade-Lauraine, Paris, FranceIsabelle Ray-Coquard, Lyon, France


HAEMATOLOGICAL MALIGNANCIES


SPECIAL SYMPOSIUMTargeting signalling pathways in haematological malignancies: Are we close to the end of histopathological classification and the chemotherapy era?Chair: Andreas Rosenwald, Würzburg, GermanyCo-Chair: Faith Davies, Sutton, UKIntroduction: Is a purely biological classification of lymphoma possible?Faith Davies, Sutton, UKTargeting kinases and relevance in B-cell lymphomas (BCL)Ingo Ringshausen, Munich, GermanyTargeting the BCL-2 pathwayAnthony Letai, Boston, MA, USTargeting the cyclinsPaolo Ghia, Milan, ItalyTranslating genetics into clinical care Thorsten Zenz, Heidelberg, GermanyConclusions: Is this the end of chemotherapy in lymphoma?Andreas Rosenwald, Würzburg, Germany


PATIENT CASES Imaging decisions in haematological malignanciesCo-Chairs: Josee Zijlstra, Amsterdam, Netherlands and Christina Messiou, Surrey, UKLymphoma: What to do and when?Josee Zijlstra, Amsterdam, NetherlandsMyeloma: What to do and when?Christina Messiou, Surrey, UKDiscussion

11:00/12:30

JOINT SYMPOSIUM: ESMO - EANMImpact of molecular imaging on management of lymphomaCo-Chairs: Michele Ghielmini, Bellinzona, Switzerland and Wim Oyen, Nijmegen, NetherlandsIntroductionWim Oyen, Nijmegen, NetherlandsPET-based decisions in Hodgkin’s lymphomaMartin Hutchings, Copenhagen, DenmarkPET-based decisions in non Hodgkin’s lymphomaJosee Zijlstra, Amsterdam, NetherlandsPotential and pitfalls in PET-imaging of lymphomaTo be announcedPET-based response criteria in lymphoma : Current status and future directionsMichel Meignan, Créteil, FranceConclusionsMichele Ghielmini, Bellinzona, Switzerland

16:00/17:30

EDUCATIONAL SESSIONMajor lymphoma subtypes in the elderlyChair: Martin Dreyling, Munich, GermanyCo-Chair: Michele Ghielmini, Bellinzona, SwitzerlandDiffuse large cell lymphoma: 8x R-CHOP 21: Is there one standard therapy for all patients? Peter Johnson, Southampton, UKFollicular lymphoma: Is it a boring disease?Martin Dreyling, Munich, GermanyChronic lymphocytic leukemia (CLL): Is treatment the same as in younger patients?Michael Hallek, Cologne, Germany

SCIENTIFIC COMMITTEEFaith Davies, Sutton, UK, Chair

Peter Campbell, Cambridge, UKEnrico Derenzini, New York, NY, USPaolo Ghia, Milan, ItalyEnrico Ocio, Salamanca, SpainGert Ossenkooppele, Amsterdam, NetherlandsMariano Provencio, Madrid, Spain

Ingo Ringshausen, Munich, GermanyAndreas Rosenwald, Wuerzburg, GermanyEvangelos Terpos, Athens, GreeceElena Zamagni, Bologna, ItalyThorsten Zenz, Heidelberg, Germany


HEAD AND NECK CANCER


CHALLENGE YOUR EXPERT (CYE)Larynx preservation: How should we decide the best treatment?Speaker: Jean-Louis Lefebvre, Lille, France

11:00/12:30

SPECIAL SYMPOSIUMPersonalised medicine in head and neck cancerChair: Sandrine Faivre, Clichy, FranceCo-Chair: Juan J. Grau, Barcelona, SpainIntroductionJuan J. Grau, Barcelona, SpainNew targets in squamous cell carcinomaJean-Pascal Machiels, Brussels, BelgiumNew targets in salivary gland cancerAndrew Futreal, Houston, TX, USImmunotherapy for head and neck cancerErik Hooijberg, Amsterdam, NetherlandsNext generation technology for next generation trialsChristophe Le Tourneau, Paris, FranceConclusion and clinical perspectivesSandrine Faivre, Clichy, France


CYE (REPETITION)Larynx preservation: How should we decide the best treatment?Speaker: Jean-Louis Lefebvre, Lille, France

11:00/12:00

MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)Locally advanced nasopharyngeal carcinomaChair: Lisa Licitra, Milan, Italy Co-Chair: Jean Bourhis, Lausanne, SwitzerlandMedical oncologyLisa Licitra, Milan, ItalyRadiotherapyJean Bourhis, Lausanne, SwitzerlandDiscussion

14:30/15:30

PATIENT CASESTreatment of medullary thyroid cancer (MTC)Co-Chairs: Jaume Capdevila, Barcelona, Spain and Sophie Leboulleux, Villejuif, FranceSub-classification and treatment of MTCSophie Leboulleux, Villejuif, FrancePractical management of tyrosine-kinase inhibitor (TKI)Jaume Capdevila, Barcelona, SpainDiscussion

SCIENTIFIC COMMITTEESandrine Faivre, Clichy, France, Chair

Jean Bourhis, Lausanne, SwitzerlandAndreas Dietz, Leipzig, GermanyCai Grau, Aarhus, DenmarkJuan José Grau, Barcelona, SpainKevin Harrington, London, UKFlorence Huguet, Paris, France

Gabriela Kornek, Vienna, AustriaChristophe Le Tourneau, Paris, FranceLisa Licitra, Milan, ItalyJean-Pascal Machiels, Brussels, BelgiumAmanda Psyrri, Athens, Greece


IMMUNOTHERAPY OF CANCER


JOINT SYMPOSIUM: ESMO - ESP Tissue markers for immuno-oncologyCo-Chairs: Fatima Carneiro, Porto, Portugal and Fortunato Ciardiello, Naples, ItalyIntroductionFortunato Ciardiello, Naples, ItalyThe importance of the preanalytical phase (the proper handling of specimens from site of biopsy to pathology lab, fixation etc) for immunohistochemistryTo be announcedHow to quantify immuohistochemical slidesTo be announcedImportance of external quality assessement in immuno-oncology To be announcedWhat the oncologist needs from the pathologistTo be announcedConclusionsFatima Carneiro, Porto, Portugal

13:00/13:45

KEYNOTE LECTUREDelivering precision immunotherapyChair: George Coukos, Lausanne, SwitzerlandSpeaker: Carl June, Philadelphia, PA, US


SPECIAL SESSION Evasion, activation and manipulation of the cancer immuno responseChair: Sjoerd van der Burg, Leiden, NetherlandsCo-Chair: Inge Marie Svane, Herlev, DenmarkIntroduction Sjoerd van der Burg, Leiden, NetherlandsOvercoming immune evasionDaniel Speiser, Lausanne, SwitzerlandPrecision medicine in immunotherapyGeorge Coukos, Lausanne, SwitzerlandBuilding rational combinations in immunotherapyMichele Maio, Siena, ItalyClinical interpretation of response with immunotherapyJohn Haanen, Amsterdam, NetherlandsConclusions and clinical perspectivesInge Marie Svane, Herlev, Denmark

16:00/17:30

EDUCATIONAL SESSIONFundamental principles of cancer immunotherapy: What the clinician needs to knowChair: Suzy Scholl, Paris, FranceCo-Chair: Ulrich Keilholz, Berlin, GermanyFundamental principles of antitumour immune response: A summary for the clinicianSuzy Scholl, Paris, FranceFundamental mechanisms of tumour immune evasion: A summary for the clinicianSjoerd van der Burg, Leiden, NetherlandsHow therapeutic immunomodulation can restore antitumour immunity: From theory to practiceMario Sznol, New Haven, CT, US


SPECIAL SYMPOSIUMActivating immune response to cancerChair: Michele Maio, Siena, Italy Co-Chair: Suzy Scholl, Paris, FranceIntroduction Suzy Scholl, Paris, FranceTumour infiltrating lymphocytes (TIL) and their use in therapyInge Marie Svane, Herlev, DanmarkAdoptive therapy with engineered T-cells Carl June, Philadelphia, PA, USNew developments in clinical vaccinationsUlrich Keilholz, Berlin, GermanyRational combinations in cancer immunotherapyIgnacio Melero, Pamplona, SpainConclusions and clinical perspectivesMichele Maio, Siena, Italy

14:30/15:30

PATIENT CASESImmunotherapy in clinical practiceCo-Chairs: Antoni Ribas, Los Angeles, CA, US and Dirk Schadendorf, Essen, GermanyChallenges in the assessment of response to cancer immunotherapyAntoni Ribas, Los Angeles, CA, USManagement of toxicity during immunotherapyDirk Schadendorf, Essen, GermanyDiscussion

SCIENTIFIC COMMITTEEGeorge Coukos, Lausanne, Switzerland, Chair

Hinrich Abken, Cologne, GermanyLuis de la Cruz Merino, Seville, SpainJohn Haanen, Amsterdam, NetherlandsRobert Hawkins, Manchester, UKUlrich Keilholz, Berlin, Germany

Michele Maio, Siena, ItalyIgnacio Melero, Pamplona, SpainSuzy Scholl, Paris, FranceInge-Marie Svane, Copenhagen, DenmarkSjoerd van der Burg, Leiden, Netherlands

24

SCIENTIFIC COMMITTEE (NSCLC, EARLY STAGE, SCLC AND OTHER THORACIC MALIGNANCIES)Johan Vansteenkiste, Leuven, Belgium, Chair

Benjamin Besse, Villejuif, FranceDirk De Ruysscher, Leuven, BelgiumWilfried Eberhardt, Essen, GermanyEric Lim, London, UKCeline Mascaux, Toronto, ON, CanadaTetsuya Mitsudomi, Osaka-Sayama, Japan

Gaetano Rocco, Naples, ItalyGiorgio Scagliotti, Orbassano, ItalyPhilipp Schnabel, Heidelberg, GermanySuresh Senan, Amsterdam, NetherlandsGiulia Veronesi, Milan, Italy

LUNG CANCER AND OTHER THORACIC MALIGNANCIES

Saturday, 27 September 2014 08:00/09:00

PATIENT CASES Therapeutic challenges in oncogene addicted lung cancersCo-Chairs: Silvia Novello, Orbassano, Italy and Ken O’Byrne, Brisbane, AustraliaA case of EGFR mutation in squamous cell carcinomaSilvia Novello, Orbassano, ItalyA ROS1 translocated NSCLC patientKen O’Byrne, Brisbane, AustraliaDiscussion

09:15/10:45

EDUCATIONAL SESSION Systemic treatment of metastatic NSCLCChair: Benjamin Besse, Villejuif, FranceCo-Chair: Lucio Crinò, Perugia, ItalyNon-oncogenic addicted NSCLC patients: What is the best approach?Benjamin Besse, Villejuif, FranceOncogenesis addiction, biomarkers: Who should be tested and when?Pasi Jånne, Boston, MA, USHow do we define progression and what is to be done?Anne-Marie Dingemans, Maastricht, Netherlands

11:00/12:30

EDUCATIONAL SESSION Clinical issues in metastatic NSCLCChair: Tony S.K. Mok, Hong Kong, ChinaCo-Chair: Jean-Yves Douillard, St.Herblain, FranceIs there anything new in squamous cells?Wilfried Eberhardt, Essen, GermanyThe best approach to oligometastatic NSCLCJaroslaw Kuzdzal, Krakow, PolandOptimal sequence of administration for targeted agentsand chemotherapyTony S.K. Mok, Hong Kong, China

14:30/15:30

PATIENT CASES Challenging cases of oligometastatic NSCLCCo-Chairs: Umberto Ricardi, Turin, Italy and Michael Thomas, Ulm, GermanyAn EGFR mutated patient with a right/left -sided located T3N0 non-squamous cell lung cancer and a solitary right/left adrenal gland metastasisMichael Thomas, Ulm, GermanyA patient with a right upper lobe peripherally located T1b adenocarcinoma with a bone metastasis in the left rib 9 and in dorsal vertebra 4 Umberto Ricardi, Turin, ItalyDiscussion

Sunday, 28 September 2014 09:00/10:30

EDUCATIONAL SESSION (REPETITION)Systemic treatment of metastatic NSCLCChair: Benjamin Besse, Villejuif, France Co-Chair: Lucio Crinò, Perugia, ItalyNon-oncogenic addicted NSCLC patients: What is the best approach?Benjamin Besse, Villejuif, FranceOncogenesis addiction, biomarkers: Who should be tested and when?Pasi Jånne, Boston, MA, USHow do we define progression and what is to be done?Anne-Marie Dingemans, Maastricht, Netherlands

11:00/12:30

EDUCATIONAL SESSION (REPETITION)Clinical issues in metastatic NSCLCChair: Tony S.K. Mok, Hong Kong, ChinaCo-Chair: Jean-Yves Douillard, St. Herblain, FranceIs there anything new in squamous cells?Wilfried Eberhardt, Essen, GermanyThe best approach to oligometastatic NSCLCJaroslaw Kuzdzal, Krakow, PolandOptimal sequence of administration for targeted agentsand chemotherapyTony S.K. Mok, Hong Kong, China

14:15/15:15

MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)Management of brain metastasis: Surgery vs radiation vs late interventionChair: Dirk De Ruysscher, Leuven, BelgiumCo-Chair: Lucio Crinò, Perugia, ItalyMedical oncologyLucio Crinò, Perugia, ItalyRadiotherapyDirk De Ruysscher, Leuven, BelgiumDiscussion


SCIENTIFIC COMMITTEE (NSCLC, METASTATIC)Solange Peters, Lausanne, Switzerland, Chair

Alex A. Adjei, Buffalo, NY, USLucio Crinò, Perugia, ItalyRafal Dziadziuszko, Gdansk, PolandKeith Kerr, Aberdeen, UKTony S.K. Mok, Hong Kong, China Silvia Novello, Orbassano, Italy

Ken O’Byrne, Brisbane, AustraliaMartin Reck, Grosshansdorf, GermanyRafael Rosell, Badalona, SpainEgbert Smit, Amsterdam, NetherlandsJames Spicer, London, UK


CHALLENGE YOUR EXPERT (CYE)SCLC: Current approaches and the role of radiotherapy (thoracic and PCI) in stage IV diseaseSpeaker: Thierry Le Chevalier, Villejuif, France

09:00/10:30

SPECIAL SYMPOSIUMThe evolving role of systemic treatment in advanced NSCLCChair: Jean-Charles Soria, Villejuif, FranceCo-Chair: Ken O’Byrne, Brisbane, AustraliaIntroductionKen O’Byrne, Brisbane, AustraliaReclassifying lung cancer and molecular diagnosticRamaswamy Govindan, St. Louis, MO, USTargeting tumour addictionRafal Dziadziuszko, Gdansk, PolandSecondary resistance to systemic treatmentEgbert Smit, Amsterdam, NetherlandsImmunotherapy: Current statusMartin Reck, Grosshansdorf, GermanyConclusions and clinical perspectivesJean-Charles Soria, Villejuif, France

16:00/17:30

SPECIAL SYMPOSIUMDiagnostic and therapeutic challenges in thoracic malignanciesChair: Johan Vansteenkiste, Leuven, BelgiumCo-Chair: Suresh Senan, Amsterdam, NetherlandsIntroductionSuresh Senan, Amsterdam, NetherlandsOptimal assessment of an additional lung nodule in a patient with potential for cure Christophe Dooms, Leuven, BelgiumWhat is the place of less invasive surgery in lung cancer?Giulia Veronesi, Milan, ItalyStereotactic ablative radiotherapy in early stage NSCLC Suresh Senan, Amsterdam, NetherlandsDefining the role of targeted therapies in early stage NSCLCSolange Peters, Lausanne, SwitzerlandConclusions and clinical perspectivesJohan Vansteenkiste, Leuven, Belgium

Tuesday, 30 September 201408:00/09:00

CYE (REPETITION) SCLC: Current approaches and the role of radiotherapy (thoracic and PCI) in stage IV diseaseSpeaker: Thierry Le Chevalier, Villejuif, France


MELANOMA AND OTHER SKIN TUMOURS


PATIENT CASES Immunotherapy or targeted therapy for oncogene addicted melanomaCo-Chairs: Anna Maria Di Giacomo, Siena, Itlay and James Larkin, London, UKChoice of immunotherapy vs targeted therapy in first line (BRAF)James Larkin, London, UKOncogene addicted brain metastasesAnna Maria Di Giacomo, Siena, ItalyDiscussion

11:00/12:30

EDUCATIONAL SESSION Skin tumours updateChair: Jürgen Becker, Graz, AustriaCo-Chair: to be announcedMerkel cell carcinomaJürgen Becker, Graz, AustriaAdjuvant treatment of melanomaOlivier Michielin, Lausanne, SwitzerlandTargeted therapy and immunotherapy for melanomaDavid Solit, New York, NY, US

16:00/17:30

SPECIAL SYMPOSIUMThe science behind combinations with immunotherapy in melanomaChair: John Haanen, Amsterdam, Netherlands Co-Chair: Christian Blank, Amsterdam, NetherlandsIntroduction Christian Blank, Amsterdam, NetherlandsThe tumour microenvironment as a barrier for immune destruction of cancerJürgen Becker, Graz, AustriaRationale to combine immunotherapy with physical therapyKevin Harrington, London, UKWhich systemic therapies should be combined to immunotherapy?Christian Blank, Amsterdam, NetherlandsCombining immunotherapiesAntoni Ribas, Los Angeles, CA, USConclusions and clinical perspectivesJohn Haanen, Amsterdam, Netherlands

SCIENTIFIC COMMITTEECaroline Robert, Villejuif, France, Chair

Paolo Ascierto, Naples, ItalyJurgen Becker, Graz, AustriaChristian Blank, Amsterdam, NetherlandsReinhard Dummer, Zurich, SwitzerlandJean-Jacques Grob, Marseille, FranceJosé Antonio López Martín, Madrid, Spain

Richard Marais, Manchester, UKGrant McArthur,Melbourne, AustraliaOlivier Michielin, Lausanne, SwitzerlandMark Middleton, Oxford, UKAntoni Ribas, Los Angeles, CA, US


NETs AND ENDOCRINE TUMOURS

Sunday,28 September 201410:30/11:30

PATIENT CASES How does one manage rare neuroendocrine malignancies?Co-Chairs: Piero Ferolla, Perugia, Italy and Alexandria Phan, Houston, TX, USMalignant bronchial carcinoid tumourPiero Ferolla, Perugia, ItalyParagangliomaAlexandria Phan, Houston, TX, USDiscussion

16:00/17:30

SPECIAL SYMPOSIUMNeuroendocrine tumours: The cutting edge and a glimpse into the futureChair: Ian Chau, Sutton, UKCo-Chair: Philippe Ruszniewski, Clichy, FranceIntroductionPhilippe Ruszniewski, Clichy, FranceTowards new molecular classification for neuroendocrine tumoursAldo Scarpa, Verona, ItalyTools to evaluate tumour response to therapy: ImagingMarie-Pierre Vullierme, Clichy, France Tools to evaluate tumour response to therapy: Tissue biomarkersTim Meyer, London, UKDo minimal access and robotic surgery bring benefit to neuroendocrine tumours?Massimo Falconi, Ancona, ItalyCurrent landscape and ongoing clinical trials for medical therapy in neuroendocrine tumoursMarianne Pavel, Berlin, GermanyClinical trial endpoints relevant to patients/society for rare tumours and conclusionsIan Chau, Sutton, UK

Monday, 29 September 201411:00/ 12:30

EDUCATIONAL SESSION Update on all neuroendocrine tumoursChair: Ian Chau, Sutton, UKCo-Chair: Alfredo Carrato, Madrid, SpainClassification and tumour biologyKjell Öberg, Uppsala, SwedenMolecular imaging and peptide receptor radionuclide therapy (PRRT)Lisa Bodei, Milan, ItalyClassical and targeted therapies in GEP-NETsIan Chau, Sutton, UK

SCIENTIFIC COMMITTEEIan Chau, Sutton, UK, Chair

Massimo Falconi, Ancona, ItalyAshley Grossman, Headington, UKDik Kwekkeboom, Rotterdam, NetherlandsSteven Libutti, New York, NY, USKjell Öberg, Uppsala, Sweden

Marianne Pavel, Berlin, GermanyAlexandria Phan, Houston, TX, USGuido Rindi, Rome, ItalyPhilippe Ruszniewski, Clichy, FranceBritt Skogseid, Uppsala, Sweden


PUBLIC HEALTH AND HEALTH ECONOMICS


PATIENT CASES Avoiding overdiagnosis and overtreatment in cancer screening: Assessing the role of personalised screeningCo-Chairs: Harry de Koning, Rotterdam, Netherlands; Silvia de Sanjose, L'Hospitalet de Llobregat, Spain and Nereo Segnan, Turin, ItalyPrecision medicine in cancer prevention: From genomic to stratified, population based cancer screeningNereo Segnan, Turin, ItalyPersonalised versus organised approaches to screening of cervical cancer: Can we fit both?Silvia de Sanjose, L'Hospitalet de Llobregat, SpainPulmonary nodules and CT-lung cancer screeningHarry de Koning, Rotterdam, NetherlandsDiscussion


SPECIAL SYMPOSIUMThe impact on health services from personalised targeted therapiesChair: Josep M. Borras, Barcelona, SpainCo-Chair: Tit Albreht, Ljubljana, SloveniaIntroductionTit Albreht, Ljubljana, SloveniaConfronting health services: Targeting the baby boomValery Lemmens, Eindhoven, NetherlandsBudget impact vs cost effectiveness: Implications for personalised cancer therapiesYolande Lievens, Ghent, BelgiumEvolution of pricing and reimbursement structure of cancer therapies in EuropeRichard Sullivan, London, UKPersonalised medicine in National Cancer Plans: How can innovation be translated into policy?Jose Maria Martin Moreno, Valencia, SpainConclusions and clinical perspectivesJosep M. Borras, Barcelona, Spain

SCIENTIFIC COMMITTEEJosep Maria Borras, Barcelona, Spain, Chair

Tit Albreht, Ljubljana, SloveniaFreddie Bray, Lyon, FranceJack Cuzick, London, UKHarry de Koning, Rotterdam, NetherlandsSivia de Sanjosé, L’Hospitalet de Llobregat, Spain

Silvano Gallus, Milan, ItalyValery Lemmens, Eindhoven, NetherlandsYolande Lievens, Ghent, BelgiumJose M. Martin-Moreno, Valencia, SpainNereo Segnan, Turin, Italy


SARCOMA


EDUCATIONAL SESSION Biology must guide the treatment in sarcomaChair: Silvia Stacchiotti, Milan, ItalyCo-Chair: Jean-Yves Blay, Lyon, FranceSarcoma pathology for cliniciansA. Paolo dei Tos, Treviso, ItalyCould medical treatment be histology guided?Silvia Stacchiotti, Milan, ItalyGastrointestinal stromal tumours (GIST)Sebastian Bauer, Essen, Germany


PATIENT CASESThe management of isolated lung metastases from soft tissue sarcomas (STS)Co-Chairs: Axel Le Cesne, Villejuif, France; Aisha Miah, London, UK and Ugo Pastorino, Milan, ItalySurgery: Why and when? Ugo Pastorino, Milan, ItalySystemic treatment for a patient with isolated lung metastases: What is the current standard?Axel Le Cesne, Villejuif, FranceThe sense and non-sense of radiotherapy and radiofrequency ablation to control isolated lung metastasesAisha Miah, London, UKDiscussion


SPECIAL SYMPOSIUMControversies in the neo-adjuvant treatment of localised soft tissue sarcomas (STS)Chair: Alessandro Gronchi, Milan, ItalyCo-Chair: Stefan Sleijfer, Rotterdam, NetherlandsIntroduction: Induction therapy in localised STS: For whom and with what?Stefan Sleijfer, Rotterdam, NetherlandsEvolving biology of sarcomaJean-Yves Blay, Lyon, FranceIs there a role for neo-adjuvant systemic treatment in STS?Javier Martin Broto, Palma de Mallorca, SpainInnovative combination of targeted agents with radiotherapyRick Haas, Amsterdam, NetherlandsLocal treatment after neo-adjuvant therapyPiotr Rutkowski, Warsaw, PolandConclusions and clinical perspectivesAlessandro Gronchi, Milan, Italy

SCIENTIFIC COMMITTEEStefan Sleijfer, Rotterdam, Netherlands, Chair

Thomas Brodowicz, Vienna, AustriaRobin Jones, Seattle, WA, USBernd Kasper, Mannheim, GermanyAxel Le Cesne, Villejuif, FranceCecile Le Pechoux, Villejuif, FranceJavier Martin Broto, Palma de Mallorca, Spain

Aisha Miah, London, UKNicolas Penel, Lille, FrancePiotr Rutkowski, Warsaw, PolandWinette van der Graaf, Nijmegen, NetherlandsKees Verhoef, Rotterdam, Netherlands


SCIENTIFIC COMMITTEEMario Dicato, Luxembourg, Chair

Raphael Catane, Tel Hashomer, IsraelPetra Feyer, Berlin, GermanyPere Gascon, Barcelona, SpainJoern Herrstedt, Odense, DenmarkIvan Krakowski, Vandoeuvre-les-Nancy, FranceAlex Molasiotis, Hong Kong, China

Carla Ripamonti, Milan, ItalyCésar Rodriguez, Salamanca, SpainFausto Roila, Terni, ItalyFlorian Scotté, Paris, FranceSimon Van Belle, Ghent, Belgium

SUPPORTIVE AND PALLIATIVE CARE


EDUCATIONAL SESSION Symptoms in oncologyChair: Carla Ripamonti, Milan, ItalyCo-Chair: Florian Strasser, St. Gallen, SwitzerlandOrgan toxicities from targeted therapiesCarla Ripamonti, Milan, Italy Metabolic disordersViktor Grünwald, Hannover, GermanyComplications arising with compliancesAndrea Antonuzzo, Pisa, Italy

11:45/12:45

PATIENT CASES Pregnancy and fertility preservation in patients with cancerCo-Chairs: Hatem A. Azim, Brussels, Belgium and Hamish Wallace, Edinburgh, UKHow to manage a pregnant woman with cancerHatem A. Azim, Brussels, BelgiumFertility preservation in the cancer patientHamish Wallace, Edinburgh, UKDiscussion

15:55/ 17:30

SPECIAL SYMPOSIUMTargeting precision medicine toxicityChair: Mario Dicato, LuxembourgCo-Chair: Fausto Roila, Terni, ItalyIntroductionMario Dicato, LuxembourgCardiac toxicityLillian Siu, Toronto, ON, CanadaPulmonary toxicityGuy Meyer, Paris, FranceSkin toxicityCaroline Robert, Villejuif, FranceEndocrine toxicityFausto Roila, Terni, ItalyOsteoarticular toxicityIgnacio Tusquets, Barcelona, SpainGI toxicityJervoise Andreyev, London, UK


CHALLENGE YOUR EXPERT (CYE)Thromboembolic disorders in oncology: Present status and novel agentsSpeaker: Mario Dicato, Luxembourg

Tuesday, 30 September 201408:00/ 09:00

CYE (REPETITION) Thromboembolic disorders in oncology: Present status and novel agentsSpeaker: Mario Dicato, Luxembourg


GENERAL INTEREST

Friday, 26 September 201412:00/ 13:15

ESMO 2014 Opening Session

ESMO Presidential AddressRolf A. Stahel, Zurich, SwitzerlandPresentation of the ESMO Award byJosep Tabernero, Barcelona, SpainESMO Award lectureTo be announcedPresentation of the ESMO Hamilton Fairley Award byJosep Tabernero, Barcelona, SpainESMO Hamilton Fairley Award lectureTo be announcedPresentation of the ESMO Lifetime Achievement Award byJosep Tabernero, Barcelona, SpainESMO Lifetime Achievement Award lectureTo be announcedESMO 2014 Scientific AddressJohann S. de Bono, Sutton, UKWelcome reception


CHALLENGE YOUR EXPERT (CYE) Is hormone therapy really harmless in elderly people?Speaker: Matti Aapro, Genolier, Switzerland

11:00/12:30

SPECIAL SESSION -ESMO COMMUNITY ONCOLOGY WORKING GROUP (COWG) Optimal use of systemic therapy in the palliative settingChair: Robert Eckert, Wendlingen, GermanyCo-Chair: Michalis Karamouzis, Athens, GreeceThe who and where of cancer care in Europe: Insights from a community oncology survey among ESMO National RepresentativesRobert Eckert, Wendlingen, Germany When to start systemic therapy: Indications for initiation of chemotherapy vs watchful waitingIan Tannock, Toronto, ON, CanadaHave a (systemic therapy) break: Optimal duration of systemic therapy in common tumoursRichard Herrmann, Basel, SwitzerlandTrials and tribulations: Lifetime experiences of a medical oncologist on chemotherapy intensificationTo be announcedIt’s time to stop: When to initiate palliative / supportive therapySofia Braga, Lisbon, Portugal ConclusionsMichalis Karamouzis, Athens, Greece

14:15/ 15:45

JOINT SYMPOSIUM: ESMO EMERGING COUNTRIES COMMITTEE (ECC) - AORTIC-SLACOM-UICC-WHOPersonalised cancer care in countries with limited resourcesDetails to be announced

16:00/ 17:30

SPECIAL SESSIONLiquid biopsy: Monitoring tumour-derived cell-free DNA, circulating tumour cells (CTC) and exosomes in patients with solid tumoursChair: Alberto Bardelli, Turin, ItalyCo-Chair: Carlos Caldas, Cambridge, UKIntroduction Carlos Caldas, Cambridge, UKClinical applications for microRNAs in lung cancerCarlo Croce, Columbus, OH, USCirculating tumour cells: Isolation, enrichment and clinical value in breast cancerMichail Ignatiadis, Brussels, BelgiumLiquid biopsies: Genotyping circulating tumour DNA in colorectal cancerAlberto Bardelli, Turin, ItalyThe potential of circulating tumour cells as a liquid biopsy to guide therapy in prostate cancerKlaus Pantel, Hamburg, GermanyNon-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNACarlos Caldas, Cambridge, UKConclusions and clinical perspectivesAlberto Bardelli, Turin, Italy



CYE (REPETITION)Is hormone therapy really harmless in elderly people?Speaker: Matti Aapro, Genolier, Switzerland

10:45/12:45

ESMO Clinical Practice Guidelines 1Chair: Enriqueta Felip, Barcelona, SpainCo-Chair: Nicholas Pavlidis, Ioannina, GreeceIntroduction to the ESMO CP GuidelinesEnriqueta Felip, Barcelona, SpainQuestionnaireNicholas Pavlidis, Ioannina, GreeceAdvanced NSCLC case presentationSpeaker: Stefan Zimmermann, Fribourg, SwitzerlandDiscussant: Solange Peters, Lausanne, SwitzerlandQuestions and answersGastric marginal zone lymphoma or MALT type case presentationSpeaker: To be announcedDiscussant: Emanuele Zucca, Bellinzona, SwitzerlandQuestions and answersHigh-grade glioma case presentationSpeaker: Katharina Seystahl, Zurich, SwitzerlandDiscussant: Roger Stupp, Zurich, SwitzerlandQuestions and answersHead & neck cancer: HPV case presentationSpeaker: To be announcedDiscussant: Lisa Licitra, Milan, ItalyQuestions and answers

13:45/15:45

ESMO Clinical Practice Guidelines 2Chair: Andrés Cervantes, Valencia, SpainCo-Chair: George Pentheroudakis, Ioannina, GreeceIntroduction to the ESMO CP GuidelinesAndrés Cervantes, Valencia, SpainQuestionnaireGeorge Pentheroudakis, Ioannina, GreeceAdvanced melanoma case presentationSpeaker: Simone Goldinger, Zurich, SwitzerlandDiscussant: Reinhard Dummer, Zurich, SwitzerlandQuestions and answersGestational trophoblastic disease case presentationSpeaker: Fieke Froeling, London, UKDiscussant: Michael Seckl, London, UKQuestions and answersWaldenström’s macroglobulinaemia case presentationSpeaker: To be announcedDiscussant: Christian Buske, Ulm, GermanyQuestions and answersCervical cancer case presentationSpeaker: To be announcedDiscussant: Cristiana Sessa, Bellinzona, SwitzerlandQuestions and answers

16:00/17:30

SPECIAL SESSION - ESMO EMERGING COUNTRIES AND PUBLIC POLICY COMMITTEES Availability of anti-neoplastic medicines in EuropeDetails to be announced

16:00/17:30

JOINT SYMPOSIUM: ESMO - EONSOral tumour therapy: Collaboration and coordination of healthcare professional activities to enhance patient adherenceCo-Chairs: Andrés Cervantes, Valencia, Spain and Anita Margulies, Zurich, Switzerland Issues and challenges in oral tumour therapy adherenceAnita Margulies, Zurich, SwitzerlandClinical issues in patients receiving oral tumour therapy: How can we improve adherence?Alfredo Carrato, Madrid, SpainNurse led clinics: Involvement in patient management and follow up To be announcedOral tumour therapy in Emerging Countries: Special problems encountered Alexandru Eniu, Cluj Napoca, RomaniaOptions and strategies: Project in action: Oral tumour therapy-adherence and safety Anita Margulies, Zurich, SwitzerlandConclusionsAndrés Cervantes, Valencia, Spain

GENERAL INTEREST



CHALLENGE YOUR EXPERT (CYE) Current diagnosis and treatment of CUPSpeaker: George Pentheroudakis, Ioannina, Greece

09:15/10:45

SPECIAL SESSIONPrecision medicine: Panacea or false dawn?Chair: Johann S. de Bono, Sutton, UKCo-Chair: José Baselga, New York, NY, USIntroductionJohann S. de Bono, Sutton, UKVisualising the true spectrum of cancer: Will we get convergence from divergence?Peter Campbell, Cambridge, UKDrug registration strategies: How will these change with precision medicine? José Baselga, New York, NY, USIntrapatient heterogeneity and clonal evolution: What precision medicine?Charles Swanton, London, UKPrecision medicine: Panacea or false dawn? Andrew Hughes, Macclesfield, UKConclusionsJohann S. de Bono, Sutton, UK

11:00/12:30

JOINT SYMPOSIUM: ESMO - ASCOThe evolution of the clinical trials landscapeCo-Chairs: Rolf A. Stahel, Zurich, Switzerland and Peter Yu, Sunnyvale, CA, USIntroduction Peter Yu, Sunnyvale, CA, USNovel molecular studies to inform the conduct of oncology clinical trials: from battle to master protocols Roy Herbst, New Haven, CT, USAdapting organisation and research infrastructures at Gustave Roussy for todays clinical research programmesAlexander M.M. Eggermont, Villejuif, FranceCan Collaborative Molecular Screening Platforms (CMSPs) support new forms of cancer clinical research? The example of the EORTC SPECTA programmeDenis Lacombe, Brussels, BelgiumThe evolution of clinical trials: Randomised controlled trials to real world studiesGary Lyman, Seattle, WA, USConclusions Rolf A. Stahel, Zurich, Switzerland

14:15/ 15:45

JOINT SYMPOSIUM: ESMO - SEOMInvestigation driven precision oncologyCo-Chairs: Rolf A. Stahel, Zurich, Switzerland andPilar Garrido, Madrid, SpainIntroductionPilar Garrido, Madrid, SpainTranslating breast cancer genomics into clinicMiguel Martin, Madrid, SpainCan we do better with our current therapies for NSCLC?The Spanish Lung Cancer Group approachRafael Rosell, Badalona, SpainTTD contribution to precision oncologyEnrique Aranda, Cordoba, SpainThe European perspective of academic research: The way to move forwardsTo be announcedConclusionsto be announced

16:00/17:30

EDUCATIONAL SESSIONCancer in young adults (18-35)Chair: Sophie Fosså, Oslo, NorwayCo-Chair: George Pentheroudakis, Ioannina, GreeceEpidemiology, risk factors, genetics and molecular biologySophie Fosså, Oslo, NorwayManaging the most common tumours affecting young adults: Peculiarities, controversies and clinical researchValerie Laurence, Paris, FranceFollow up and long term toxicity of young adult cancer survivorsDaniel Stark, Leeds, UK

16:00/17:30

SPECIAL SESSION - RARE CANCERS EUROPE How clinical trials could have been done, and were not, in rare cancersDetails to be announced

Tuesday, 30 September 201408.00/ 09:00

CYE (REPETITION)Current diagnosis and treatment of CUPSpeaker: George Pentheroudakis, Ioannina, Greece

09:00/13:00

CONGRESS HIGHLIGHTSThe best of the ESMO 2014 Congress

Controversy sessions will be included in the programme and details will be made available at the same time as the abstract-related sessions


YOUNG ONCOLOGISTS (YO)

Friday, 26 September 201414:00/17:00

YO MASTERCLASSESMO YOs meet the EACR: Integrating basic science into clinical researchChair: Raffaele Califano, Manchester, UK Co-Chair: Leticia De Mattos-Arruda, Barcelona, SpainFunctional characterisation of tumours using patient-derived models - therapeutic implicationsSpeaker: Joan Seoane, Barcelona, SpainSession Shooter: Matthias Preusser, Vienna, AustriaInter and intra-tumour genetic heterogeneity: Challenges for targeted therapySpeaker: Carlos Caldas, Cambridge, UKSession Shooter: Erika Martinelli, Naples, Italy Circulating biomarkers: What does this mean today?Speaker: Klaus Pantel, Hamburg, GermanySession Shooter: Sophie Postel-Vinay, London, UKNext generation of clinical trial designSpeaker: Timothy Yap, Sutton, UKSession Shooter: Jesus Corral, Seville, Spain

17:15/17:45

VESALIUS TALKPaving your own path to successMentors: Christoph Zielinski, Vienna, Austria; Angelo Di Leo, Prato, Italy and Nicholas Pavlidis, Ioannina, Greece


YO BREAKFASTHow to address the media: Practical advice for young oncologistsSession Coordinators: Margaret Hutka, London, UK and Matthias Preusser, Vienna, AustriaSpeaker: Jilly Carter, Wallingford, UK

Sunday, 28 September 201408:00/ 08:45

YO BREAKFASTHow to find the right work-life balance: Time management for young oncologistsSession Coordinators: Giannis Mountzios, Athens, Greece and Susana Banerjee, London, UKSpeaker: Pia Osterlund, Helsinki, Finland


YO BREAKFASTRisks and boundaries: The doctor / cancer patient relationshipSession Coordinators: Mila Petrova, Sofia, Bulgaria and Valentina Guarneri, Padua, ItalySpeaker: Lesley Fallowfield, Brighton, UK

09:00/10:30

YO FORUM Tips and tricks for cancer researchers in trainingChair: Valentina Guarneri, Padua, ItalyCo-Chair: Karin Jordan, Halle, GermanyThe ideal mentor and the impact on your careerSpeaker: Peter Schmid, London, UK Session Shooter: Mila Petrova, Sofia, BulgariaPractical advice on how to write a clinical trial protocolSpeaker: To be announcedSession Shooter: Nikita Volkov, St. Petersburg, Russian FederationThe importance of a well written grant applicationSpeaker: Fatima Cardoso, Lisbon, PortugalSession Shooter: Sophie Postel-Vinay, London, UKResearch project completed - now write your paper!Speaker: Kari Skinningsrud, Lillestrøm, NorwaySession Shooter: Camilla Qvortrup, Odense, Denmark

11:00/12:30

YO SPECIAL SESSIONFellowships in Europe: Educational opportunities for young oncologistsChair: Giampaolo Tortora, Verona, Italy Co-Chair: Raffaele Califano, Manchester, UKIntroductionGiampaolo Tortora, Verona, ItalyThe ESMO Fellowship ProgrammeSusana Banerjee, London, UKPractical tips from a former fellow Leticia De Mattos-Arruda, Barcelona, SpainBest fellowship project 1Floriana Morgillo, Naples, ItalyBest fellowship project 2Hatem A. Azim, Brussels, BelgiumConclusionsRaffaele Califano, Manchester, UK and Giampaolo Tortora, Verona, ItalyAwards: Presentation of the ESMO 2014 fellows and the 2013 best exam

YOUNG ONCOLOGISTS COMMITTEERaffaele Califano, Manchester, UK, Chair

Susana Banerjee, London, UKJesus Corral, Seville, SpainEvandro De Azambuja, Brussels, BelgiumLeticia De Mattos-Arruda, Barcelona, SpainValentina Guarneri, Padova, ItalyMargaret Hutka, London, UKKarin Jordan, Halle, Germany

Erika Martinelli, Naples, ItalyGiannis Mountzios, Athens, GreeceMila Petrova, Sofia, BulgariaSophie Postel-Vinay, London, UKMatthias Preusser, Vienna, AustriaCamilla Qvortrup, Odense, DenmarkNikita Volkov, St. Petersburg, Russian Federation

THE ONLINE ACCESS TO ESMO’S SCIENTIFIC AND EDUCATIONAL CONTENT.Your one-stop shop for exclusive medical oncology content, from news and conference presentations to guidelines, handbooks and treatment factsheets. All available at your desk, or on the go.

MEDICAL ONCOLOGY IS A FAST-EVOLVING FIELD, ONCOLOGYPRO WILL HELP YOU KEEP UP-TO-DATE.oncologypro.esmo.org

Main sponsors

Major sponsors

FIND WHAT YOU’RE LOOKING FOR ON ONCOLOGYPRO

STOP SEARCHINGSTART FINDING

ESM_OncoPRO2014_Ad_AdvProgramme_210x297mm.indd 1 07/03/14 13:28



Cancer research

Clinical trials: Making statistics a little bit easier to understand!

Clinical trials – Endpoints

Patient involvement in cancer clinical research

Introduction: Generating patient data, tissue and experiences…

14:00/15:30

Treatment & living (part 1)

ESMO Patient Cancer Guides

Cancer & nutrition

16:00/17:45

Treatment & living (part 2)

Patient interaction with multidisciplinary teams (MDTs)

Highlighting some social challenges

17:45 End of the 1st day – Get together / Networking

PATIENT ADVOCACY TRACK


Capacity building

The ESMO “Patient Advocacy Best Practice Award” 2014

Why strategic planning is important and valuable for patient groups?

14:00/15:30

Patient advocacy (Part 1)

An interesting journey through European healthcare politics

RARE CANCERS in EUROPE: More common than you think!

16:00/17:30

Patient advocacy (Part 2)

European cross border healthcare directive

17:30 End of the 2nd day – Farewell

ESMO PATIENT ADVOCACY TRACK TASK FORCELorenz Jost, Kantonsspital and Chair of the ESMO CPWG Switzerland

Raphael Catane Sheba Medical Centre, IsraelPhilip Davies European Cervical Cancer Association, UKFrancesco De Lorenzo European Cancer Patient Coalition, ItalyLouis Denis Europa Uomo, BelgiumJan Geissler CML Advocates Network, GermanyGabriela Kornek Medical University of Vienna, AustriaStella Kyriakides Europa Donna Cyprus, Cyprus

Anita Margulies European Oncology Nursing Society, SwitzerlandKathy Oilver International Brain Tumours Alliance, UKZorana Stokic Europacolon, SerbiaWendy Tse Yared Association of European Cancer Leagues, BelgiumStefania Vallone Global Lung Cancer Coalition, ItalyAnita Waldmann Myeloma Euronet, GermanyMarkus Wartenberg Sarcoma Patients EuroNet, IKCC, Germany

Final details of the programme will be published online at esmocongress.org

esmocongress.org

esmo 2014 advanced programme · management of breast cancer in elderly patients etienne brain,...

Documents